Expression of Peroxisome Proliferator Activated Receptor gamma in Prostatic Adenocarcinoma
- Authors
- Park, Hyung Kyu; Kim, HyunKyung; Kim, Hyeong-Gon; Cho, Young Mee; Jung, Woon Yong; Han, Hye Seung; Hwang, Tae Sook; Kwon, Ghee Young; Lim, So Dug
- Issue Date
- May-2015
- Publisher
- KOREAN ACAD MEDICAL SCIENCES
- Keywords
- Prostatic Neoplasms; PPAR gamma; Immunohistochemistry; Real-Time Polymerase Chain Reaction
- Citation
- JOURNAL OF KOREAN MEDICAL SCIENCE, v.30, no.5, pp.533 - 541
- Indexed
- SCIE
SCOPUS
KCI
- Journal Title
- JOURNAL OF KOREAN MEDICAL SCIENCE
- Volume
- 30
- Number
- 5
- Start Page
- 533
- End Page
- 541
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/157224
- DOI
- 10.3346/jkms.2015.30.5.533
- ISSN
- 1011-8934
- Abstract
- Peroxisome proliferator-activated receptor gamma (PPAR-gamma), a ligand-activated transcription factor has been investigated as the target for cancer treatment as well as metabolic disorders. Recent studies have demonstrated that PPAR-gamma ligands are anti-tumorigenic in prostate cancer due to anti-proliferative and pro-differentiation effects. The aim of this study was to validate PPAR-gamma expression in malignant and benign prostate tissues by immunohistochemistry and quantitative real-time polymerase chain reaction (PCR). A total of 730 prostatic adenocarcinomas (PCAs) including 63 whole sections from radical prostatectomy specimens and tissue microarrays containing 667 PCAs were subject to immunostaining for two PPAR-gamma antibodies. Twenty-five benign prostate tissues and PCAs were selected for investigating mRNA expression by quantitative real-time PCR. 10.7% of PCAs (78/730) showed cytoplasmic immunoreactivity of PPAR-gamma and no nuclear immunoreactivity was noted in PCAs. Most benign prostatic glands showed negative immunoreactivity of PPAR-gamma except for variable weak cytoplasmic staining in some glands. Nuclear immunoreactivity of PPAR-gamma was noted some central zone and verumontanum mucosal epithelium. The constitutive PPAR-gamma mRNA showed significantly lower level in PCAs compared to that in the benign tissues. There was no difference of PPAR-gamma mRNA expression between low (<= 7) and high (> 7) Gleason score groups. There was no association of PPAR-gamma mRNA level or cytoplasmic immunostaining with Gleason grade or pathologic stage. Our study supported the evidence of extra-nuclear localization and nongenomic actions of PPAR-gamma. Further studies are needed to assess the functional role of PPAR-gamma and to validate its therapeutic implication in prostate cancer.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 서울 의과대학 > 서울 병리학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/157224)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.